ELVN — Enliven Therapeutics
Median target
$74
calls from the last 12 months
Implied return
+47.3%
median target vs. price
Coverage
12 analysts · 12 calls
updated in the last 12 months
Consensus
12/0/0+12 net
Buy / Hold / Sell
Which analysts are behind ELVN's consensus?
See every current rating, price target and the analysts' track records for Enliven Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 12 analysts with calls on ELVN updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
ELVN elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-17 | Insiders | Hohl BenjaminCHIEF FINANCIAL OFFICER | Insider sale | 4.6K sh @ $58.35 · planned trade | $270K |
| 2026-08-17 | Insiders | Collins Helen LouiseCHIEF MEDICAL OFFICER | Insider sale | 3.9K sh @ $58.37 · planned trade | $228K |
| 2026-08-17 | Insiders | Hohl BenjaminCHIEF FINANCIAL OFFICER | Insider sale | 1.4K sh @ $59.35 · planned trade | $82K |
| 2026-08-17 | Insiders | Collins Helen LouiseCHIEF MEDICAL OFFICER | Insider sale | 1.1K sh @ $59.35 · planned trade | $65K |
| 2026-08-04 | Insiders | Derynck Mika KDirector | Insider sale | 158.8K sh @ $60.21 · planned trade | $9.6M |
More: insider activity · executive branch · trending